Recce Pharmaceuticals Ltd (ASX: RCE) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Recce Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$72.42 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
249.73 million
Earnings per share
-0.091
Dividend per share
N/A
Year To Date Return
-39.63%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Recce Pharmaceuticals Ltd (ASX: RCE)
Latest News
Share Gainers
Why the Recce Pharmaceuticals (ASX:REE) share price is storming higher today
Healthcare Shares
Why is the Recce (ASX:RCE) share price falling today?
Healthcare Shares
Recce (ASX:RCE) share price surges 6% on clinical trial registration
Share Gainers
The Recce (ASX:RCE) share price is up 7% after its drug saved a human
Share Gainers
Why EML, NextDC, Qantas, & Recce shares are racing higher
Healthcare Shares
Why is the Recce (ASX:RCE) share price in the red today?
Share Fallers
Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update
Share Gainers
Here's why the Recce (ASX:RCE) share price is racing higher today
Share Gainers
Why Novonix, Recce, Singular Health, & Starpharma shares are storming higher
Share Gainers
Why the Recce Pharmaceuticals (ASX:RCE) share price is rocketing 10% higher
Share Gainers
Why a2 Milk, Air New Zealand, Mesoblast, & Recce shares are storming higher
Share Gainers
Recce (ASX:RCE) share price charges higher on COVID-19 update
RCE ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibioticdrugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.
RCE Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 May 2025 | $0.29 | $0.00 | 0.00% | 70,037 | $0.29 | $0.30 | $0.29 |
| 01 May 2025 | $0.29 | $0.00 | 0.00% | 24,364 | $0.29 | $0.29 | $0.29 |
| 30 Apr 2025 | $0.29 | $0.00 | 0.00% | 332,060 | $0.29 | $0.29 | $0.28 |
| 29 Apr 2025 | $0.29 | $0.01 | 3.51% | 46,939 | $0.29 | $0.29 | $0.29 |
| 28 Apr 2025 | $0.29 | $-0.01 | -3.45% | 443,666 | $0.29 | $0.30 | $0.29 |
| 24 Apr 2025 | $0.29 | $0.00 | 0.00% | 92,674 | $0.29 | $0.29 | $0.28 |
| 23 Apr 2025 | $0.29 | $0.01 | 3.57% | 114,505 | $0.29 | $0.29 | $0.28 |
| 22 Apr 2025 | $0.28 | $-0.01 | -3.45% | 336,250 | $0.29 | $0.29 | $0.28 |
| 17 Apr 2025 | $0.29 | $0.01 | 3.51% | 23,973 | $0.29 | $0.29 | $0.29 |
| 16 Apr 2025 | $0.29 | $-0.01 | -3.45% | 110,812 | $0.30 | $0.30 | $0.29 |
| 15 Apr 2025 | $0.29 | $-0.01 | -3.37% | 304,779 | $0.30 | $0.30 | $0.28 |
| 14 Apr 2025 | $0.30 | $0.01 | 3.48% | 191,308 | $0.30 | $0.30 | $0.28 |
| 11 Apr 2025 | $0.29 | $-0.01 | -3.37% | 174,159 | $0.30 | $0.30 | $0.29 |
| 10 Apr 2025 | $0.30 | $-0.02 | -6.21% | 836,540 | $0.33 | $0.33 | $0.29 |
| 09 Apr 2025 | $0.32 | $-0.02 | -5.85% | 279,957 | $0.34 | $0.34 | $0.32 |
| 08 Apr 2025 | $0.34 | $0.01 | 3.06% | 29,440 | $0.34 | $0.34 | $0.33 |
| 07 Apr 2025 | $0.33 | $-0.02 | -5.69% | 171,471 | $0.35 | $0.35 | $0.32 |
| 04 Apr 2025 | $0.35 | $-0.01 | -2.73% | 67,756 | $0.37 | $0.37 | $0.35 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 14 Nov 2024 | James Graham | Issued | 3,000,000 | $732,000 |
Issue of options. Black Scholes option
valuation methodology, estimated value |
| 14 Nov 2024 | Alistair McKeough | Issued | 1,000,000 | $244,000 |
Issue of options. Black Scholes option
valuation methodology, estimated value |
| 14 Nov 2024 | Alan Dunton | Issued | 2,250,000 | $549,000 |
Issue of options. Black Scholes option
valuation methodology, estimated value |
| 14 Nov 2024 | Michele Dilizia | Issued | 1,600,000 | $390,400 |
Issue of options. Black Scholes option
valuation methodology, estimated value |
| 14 Nov 2024 | John Prendergast | Issued | 2,650,000 | $646,600 |
Issue of options. Black Scholes option
valuation methodology, estimated value |
| 14 Nov 2024 | Justin Ward | Issued | 1,000,000 | $244,000 |
Issue of options. Black Scholes option
valuation methodology. |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr James Hamilton Bray Graham | Managing DirectorExecutive DirectorChief Executive Officer | Jun 2015 |
Mr Graham has experience in marketing, business development and commercialisation of early-stage technologies with global potential.
|
| Mr Alistair Gregory McKeough | Non-Executive Director | Nov 2017 |
Mr McKeough is an experienced executive and solicitor. He has experience serving as a director in many sectors, including for companies involved in professional services, corporate services, regulatory technology, sports technology, charities, health, biotech, childcare and education. He is the Chair of Risk Committee.
|
| Dr Alan William Dunton | Chief Medical AdvisorNon-Executive Director | Jul 2020 |
Dr Dunton brings experience with over three decades in senior pharmaceutical roles. Notably, he served as the President and Managing Director of the Janssen Research Foundation (J&J Research). He is a member of Risk Committee.
|
| Ms Michele Keryn Dilizia | Chief Scientific OfficerExecutive Director | Jun 2015 |
Ms Dilizia is a co-inventor and qualified medical scientist with a specialisation in medical microbiology and regulatory affairs. She successfully co-led the research and development of Recce's suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).
|
| Dr John Prendergast | Executive ChairmanExecutive Director | Apr 2018 |
Dr Prendergast is an executive in the pharmaceutical industry. Currently serving as the Chairman and Co-founder of Palatin Technologies, Inc. and the Lead Director of Nighthawk Biosciences (NYSE: HHWK), he brings over three decades of experience in the commercialisation of pharmaceutical technologies. He is a member of Risk Committee.
|
| Dr Justin Leigh Ward | Executive Director | Jul 2019 |
Dr Ward is a qualified Chemist and Pharmacist with over 20 years of pharmaceutical and biotech industry experience in quality control, quality assurance, product research and development with leading pharmaceutical companies, including Pfizer. Dr Ward previously held a technical role with Pfizer, involving providing data for regulatory submissions to the FDA and TGA.
|
| Ms Maggie Niewidok | Company Secretary | Sep 2022 |
-
|
| Justin Reynolds | Chief Financial Officer |
-
|
|
| Maggie Niewidok | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Graham John Hamilton Melrose & Ms Olga Mary Melrose | 32,353,311 | 13.97% |
| HSBC Custody Nominees (Australia) Limited | 14,970,467 | 6.46% |
| Buttonwood Nominees Pty Ltd | 9,720,451 | 4.20% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 7,700,000 | 3.32% |
| BNP Paribas Noms Pty Ltd | 7,076,356 | 3.06% |
| Acuity Capital Investment Management Pty Ltd <Acuity Capital Holdings A/C> | 4,500,000 | 1.94% |
| Acewood Investments Pty Ltd <Chivers Super Fund A/C> | 3,537,101 | 1.53% |
| Pejay Pty Limited | 3,300,000 | 1.42% |
| Mr John James Liddelow <John Liddelow A/C> | 3,200,000 | 1.38% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 2,986,111 | 1.29% |
| Ms Michele Keryn Dilizia | 2,828,485 | 1.22% |
| Mr Arthur Nicholas Veliss & Mr Mark Anthony Rogers <Artmark Super Fund A/C> | 2,500,000 | 1.08% |
| Mr Graham Melrose & Ms Olga Melrose | 2,475,000 | 1.07% |
| J P Morgan Nominees Australia Pty Limited | 2,177,007 | 0.94% |
| Querion Pty Ltd | 2,100,000 | 0.91% |
| Seneschal (WA) Pty Ltd <Winston Scotney Family S A/C> | 2,066,666 | 0.89% |
| Citicorp Nominees Pty Limited | 1,964,710 | 0.85% |
| LDU Pty Ltd <Vesty Super Fund A/C> | 1,933,219 | 0.83% |
| Haultrans Management Pty Limited <Successful Super Fund A/C> | 1,870,000 | 0.81% |
| Mr John James Liddelow | 1,605,000 | 0.69% |